Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Impact of Growth Hormone Co-Treatment Duration on Outcomes in Ivf/ Icsi Cycles Among Poor Ovarian Responders Publisher



Mohammadshirazi Z1 ; Alyasin A2 ; Hosseini MA2 ; Hazari V3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Obstetrics and Gynecology, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran
  2. 2. Department of Obstetrics and Gynecology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Obstetrics and Gynecology, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran
  4. 4. Rooyesh Infertility Center, Birjand University of Medical Sciences, Birjand, Iran

Source: Journal of Reproduction and Infertility Published:2023


Abstract

Background: The efficiency of in vitro fertilization is improved by growth hormone (GH) during ovarian stimulation. Additionally, patients with diabetes experience impaired insulin resistance and compromised glucose tolerance, which further exacerbate their condition. Due to these side effects, in this study, the duration of GH treatment was compared in IVF/ICSI cycles among poor ovarian responders. Methods: In this study, POSEIDON criteria were used to choose patients. Subcutaneous administration of gonadotropin-releasing hormone (GnRH) antagonist was done beginning on the sixth day of the cycle and continuing through the day of human chorionic gonadotropin (hCG) injection. In one group, GH was administered 4 units/day from the 2nd day of the cycle until hCG injection, and in another group, the first dose was administered on the 6th day of the cycle. Following the administration of hCG, which lasted from 24 to 36 hr, oocytes were retrieved with the support of B-mode sonography. Results: In our analysis, no significant differences were observed between the two groups in terms of the number of retrieved oocytes, metaphase II oocytes, and quality of grade A and B embryos. The results show that the treatment or conditions did not have a significant impact on the outcomes among the studied groups. Conclusion: Our findings indicate that a shorter duration of GH administration can yield similar outcomes compared to a longer duration in IVF/ICSI cycles involving poor ovarian responders. This result holds the potential for a more cost-effective and patient-friendly approach in managing assisted reproductive technology procedures. It may lead to reduced side effects and improved adherence to medication regimens in patients. © 2023, Journal of Reproduction & Infertility. All rights reserved.
Related Docs
1. The Effect of Intrauterine Administration of Growth Hormone on Ivf Success Rate in Recurrent Implantation Failure Women: A Randomized Clinical Trial, Iranian Journal of Pharmaceutical Research (2024)
2. Astaxanthin Improves Assisted Reproductive Technology Outcomes in Poor Ovarian Responders Through Alleviating Oxidative Stress, Inflammation, and Apoptosis: A Randomized Clinical Trial, Journal of Ovarian Research (2024)
3. Astaxanthin Treatment Decreases Pro‐Inflammatory Cytokines and Improves Reproductive Outcomes in Patients With Polycystic Ovary Syndrome Undergoing Assisted Reproductive Technology: A Randomized Clinical Trial, Inflammopharmacology (2024)
4. Growth Hormone (Gh) Improvement of Ovarian Responses and Pregnancy Outcome in Poor Ovarian Responders: A Randomized Study, Asian Pacific Journal of Cancer Prevention (2019)
5. Effect of Pyridostigmine on Growth Hormone and Igf-1 Levels and Outcomes of Controlled Ovarian Stimulation Cycle in Women With Poor Ovarian Response, Archives of Gynecology and Obstetrics (2025)
Experts (# of related papers)
View all Related Experts
Fardin Amidi (2)
Ashraf Aleyassin (2)